<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538638</url>
  </required_header>
  <id_info>
    <org_study_id>NL61632.018.18</org_study_id>
    <nct_id>NCT04538638</nct_id>
  </id_info>
  <brief_title>Mesenteric SParIng Versus Central mesenterectomY in Ileocolic Resection for Terminal Ileitis in Crohn's Disease</brief_title>
  <acronym>SPICY</acronym>
  <official_title>Mesenteric SParIng Versus Central mesenterectomY in Ileocolic Resection for Terminal Ileitis in Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this multicenter randomised controlled trial is to analyse the six month&#xD;
      endoscopic recurrence following a mesenteric sparing versus a central mesenterectomy&#xD;
      performing an ileocolic resection for CD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is emerging evidence to suggest that Crohn's disease (CD) may be a disease of the&#xD;
      mesentery rather than just of the bowel alone. A more extensive central mesenterectomy (up to&#xD;
      the level of the ileocolic artery), in order to remove an increased volume of affected&#xD;
      mesentery to prevent postoperative CD, has been suggested to lead to beneficial results. It&#xD;
      is hypothesised that patients who undergo a central mesenterectomy during an ileocolic&#xD;
      resection compared to a mesenteric sparing ileocolic resection will have decreased recurrence&#xD;
      rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with Crohn's disease will be randomised in a 1:1 ratio for mesenteric sparing versus central mesenterectomy when performing an ileocolic resection for Crohn's disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>There is no blinding to the treatment allocation for the treating surgeon. The treatment will be blinded for the treating gastroenterologist, the endoscopist and the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The post-operative endoscopic recurrence of Crohn's disease at six months following ileocolic resection</measure>
    <time_frame>6 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic and clinical recurrence rate at 6 months following ileocolic resection</measure>
    <time_frame>6 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for restarting immunosuppressive medication within the first year postoperatively for endoscopic or clinical recurrence</measure>
    <time_frame>1 year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 5 year reoperation rate for recurrence of disease at the anastomotic site.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Mesenteric Sparing ileocolic resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard procedure for CD, ileocolic resection without removal of the mesentery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central mesenterectomy ileocolic resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental procedure for CD: ileocolic resection in which the mesentery is taken up to the level of the ileocolic trunc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mesenteric sparing ileocolic resection</intervention_name>
    <description>Mesentery left in situ</description>
    <arm_group_label>Mesenteric Sparing ileocolic resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Central mesenterectomy ileocolic resection</intervention_name>
    <description>Mesentery is taken up to the level of the ileocolic trunk</description>
    <arm_group_label>Central mesenterectomy ileocolic resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, a subject must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Ileocolic disease with an indication for ileocecal resection&#xD;
&#xD;
          2. Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics,&#xD;
             and anti-TNF therapy are permitted.&#xD;
&#xD;
          3. All patients should have undergone a colonoscopy and MR enterography (or CT&#xD;
             enterography if MR contraindicated) in last 3 months to assess extent of disease.&#xD;
&#xD;
          4. Ability to comply with protocol.&#xD;
&#xD;
          5. Competent and able to provide written informed consent.&#xD;
&#xD;
          6. Patient must have been discussed in the local MDT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A potential subject who meets any of the following criteria will be excluded from&#xD;
        participation in this study:&#xD;
&#xD;
          1. Inability to give informed consent.&#xD;
&#xD;
          2. patients less than 16 years of age.&#xD;
&#xD;
          3. Patients undergoing repeated ileocolic resection.&#xD;
&#xD;
          4. Clinically significant medical conditions within the six months before the operation :&#xD;
             e.g. myocardial infarction, active angina, congestive heart failure or other&#xD;
             conditions that would, in the opinion of the investigators, compromise the safety of&#xD;
             the patient.&#xD;
&#xD;
          5. History of cancer &lt; 5 years which might influence patients prognosis&#xD;
&#xD;
          6. Emergent operation.&#xD;
&#xD;
          7. Pregnant or breast feeding.&#xD;
&#xD;
          8. Inability to follow up at 3, 6 and 12 months for postoperative assessment, imaging and&#xD;
             endoscopy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christianne J Buskens</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam UMC, location AMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Willem A Bemelman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam UMC, location AMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christianne J Buskens</last_name>
    <phone>0031205662771</phone>
    <email>c.j.buskens@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC - Location AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Meibergdreef 9</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eline ML van der Does, MD</last_name>
      <phone>0031205662771</phone>
      <email>e.vanderdoesdewillebois@amsterdamumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. dr. W.A. Bemelman</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Ileocolic</keyword>
  <keyword>Mesenteric Sparing</keyword>
  <keyword>Extended Mesenterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Ileitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

